INCYTE CORPORATION;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
发明人:
REUTHER, GARY,KOBLISH, HOLLY
申请号：
ARP180103598
公开号：
AR113922A1
申请日:
2018.12.07
申请国别(地区):
AR
年份:
2020
代理人:
摘要：
1. This application relates to the treatment of diffuse bone tumors with Jak1 / JAK2, ruxotinib inhibitor, plus N - (7R) - 4 - [(3R, 4R, 5S) - 3-amino-4-hydroxi-5-methylpieridin-1-il] - 7-hydroxi-6, 7-dihydro-5h-cyclopenta [b] piridin-3-il} - 6 - (2) 6-fluorodifluorophenyl-5-fluoroopiridina-2-carboxamida, in this case, the mixture can unexpectedly synergize at very low levels of PIM inhibitors.La presente solicitud se refiere al tratamiento de neoplasias mieloproliferativas que utiliza el inhibidor de JAK1 / JAK2, ruxolitinib, en combinación con una dosis baja de un inhibidor de Pim, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hidroxi-5-metilpiperidin-1-il]-7-hidroxi-6,7-dihidro-5H-ciclopenta[b]piridin-3-il}-6-(2,6-difluorofenil)-5-fluoropiridina-2-carboxamida, donde la combinación es inesperadamente sinérgica a una dosis muy baja del inhibidor de Pim.
